Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JBM (Healthcare)HKSE:02161 86 OCF Margin % is 17.40% as of Mar. 2026, which is 11% below its 10-year median of 19.46. GuruFocus rates HKSE:02161 with a GF Score™ of 86/100 and a GF Value™ of HK$2.08 (Fairly Valued). The stock has 4 warning signs investors should review. Among 964 Drug Manufacturers companies, JBM (Healthcare) ranks better than 76.76% on this metric.
The historical rank and industry rank for JBM (Healthcare)'s OCF Margin % or its related term are showing as below:
HKSE:02161'
s OCF Margin % Range Over the Past 10 Years
Min: 10.03 Med: 19.46 Max: 31.14
Current: 19.46
During the past 9 years, the highest OCF Margin % of JBM (Healthcare) was 31.14%. The lowest was 10.03%. And the median was 19.46%.
HKSE:02161's OCF Margin % is ranked better than 76.76% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs HKSE:02161: 19.46
The historical data trend for JBM (Healthcare)'s OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JBM (Healthcare) OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s OCF Margin % distribution charts can be found below:
* The bar in red indicates where JBM (Healthcare)'s OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JBM (Healthcare) (HKSE:02161) has a OCF Margin % of 17.40% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on JBM (Healthcare) and its competitors. This is 11% below median its historical median of 19.46. Over the past decade, JBM (Healthcare)'s OCF Margin % has ranged from 10.03 to 31.14. According to the industry distribution chart, JBM (Healthcare) ranks #224 out of 964 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is JBM (Healthcare)'s OCF Margin % too high?
JBM (Healthcare)'s current OCF Margin % of 17.40% is 11% below median its 10-year median of 19.46. Over the past 10 years, this metric has ranged from a low of 10.03 to a high of 31.14. The Drug Manufacturers industry median OCF Margin % is 10.04. JBM (Healthcare)'s value of 17.40% is 73.4% above this industry median. Based on the distribution chart, JBM (Healthcare) ranks #224 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JBM (Healthcare) ranks #224 out of 964 companies for OCF Margin %. This places JBM (Healthcare) in the top 23% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.04. JBM (Healthcare)'s value of 17.40% is 73.4% above this benchmark. Historically, JBM (Healthcare)'s own OCF Margin % has ranged from 10.03 to 31.14 over the past decade. While the company's 10-year median is 19.46 vs. the industry median of 10.04, JBM (Healthcare) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JBM (Healthcare)'s current OCF Margin % of 17.40% is 73.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on JBM (Healthcare) and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JBM (Healthcare)'s current OCF Margin % is 17.40%, which is 11% below median its own 10-year median of 19.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.94 — trading 6.7% below its estimated fair value. The current OCF Margin % is 17.40%, which is 11% below median its 10-year median of 19.46 and 73.4% above the Drug Manufacturers industry median of 10.04. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current OCF Margin % is 17.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.94 is trading 6.7% below its estimated GF Value™ of HK$2.08.
GuruFocus considers JBM (Healthcare) to be Fairly Valued.
Key valuation signals for HKSE:02161:
OCF Margin %: 17.40% (11% below median its 10-year median of 19.46)
GF Value™: HK$2.08 vs. price of HK$1.94 (6.7% below fair value)
Industry Position: 73.4% above the Drug Manufacturers median (#224 of 964)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
